Antares Therapeutics Enters Agreement with Novartis to Discover, Develop and Commercialize First-in-Class Cancer Therapies

Antares Therapeutics Enters Agreement with Novartis to Discover, Develop and Commercialize First-in-Class Cancer Therapies

BOSTON--(BUSINESS WIRE)--Jun 24, 2026-

Novartis signs up to $1.9bn deal to tap Antares’ undruggable-target engine - European Biotechnology Magazine

Novartis has signed a multi-target oncology discovery deal with Antares Therapeutics, paying $105m upfront for access to the Boston biotech’s small-molecule discovery engine. The agreement could bring Antares up to $1.8bn more in option, development, regulatory and commercial milestones, plus tiered royalties on global net sales that could reach the low double-digit range. The post Novartis signs up to $1.9bn deal to tap Antares’ undruggable-tar…

Novartis taps Antares in small molecule discovery pact with $105M upfront

Antares Therapeutics will be collaborating with Novartis to find unique small molecule candidates for multiple “undruggable” cancer targets, with the biotech receiving $105 million upfront. “We're discovering and developing with Novartis targets that have never ...